Biotech's CEO says its lead respiratory candidate RV521 has 'caught up with rivals' in efficacy and safety.
ReViral Ltd. will use the $55m newly raised in a Series B Financing to begin a global, multi-center Phase IIa trial next year testing its lead asset RV521 in babies suffering from respiratory syncytial virus (RSV), and then move the investigational compound into adult stem cell transplant patients later in 2019, its CEO told Scrip.
The Series B financing, jointly led by New Leaf Venture Partners and Novo Ventures, had additional new investment from Perceptive...
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
